An injectable shear-thinning biomaterial for endovascular embolization

Reginald K. Avery, Hassan Albadawi, Mohsen Akbari, Yu Shrike Zhang, Michael J. Duggan, Dushyant V. Sahani, Bradley D. Olsen, Ali Khademhosseini, Rahmi Oklu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Improved endovascular embolization of vascular conditions can generate better patient outcomes and minimize the need for repeat procedures. However, many embolic materials, such as metallic coils or liquid embolic agents, are associated with limitations and complications such as breakthrough bleeding, coil migration, coil compaction, recanalization, adhesion of the catheter to the embolic agent, or toxicity. Here, we engineered a shear-thinning biomaterial (STB), a nanocomposite hydrogel containing gelatin and silicate nanoplatelets, to function as an embolic agent for endovascular embolization procedures. STBs are injectable through clinical catheters and needles and have hemostatic activity comparable to metallic coils, the current gold standard. In addition, STBs withstand physiological pressures without fragmentation or displacement in elastomeric channels in vitro and in explant vessels ex vivo. In vitro experiments also indicated that STB embolization did not rely on intrinsic thrombosis as coils did for occlusion, suggesting that the biomaterial may be suitable for use in patients on anticoagulation therapy or those with coagulopathy. Using computed tomography imaging, the biomaterial was shown to fully occlude murine and porcine vasculature in vivo and remain at the site of injection without fragmentation or nontarget embolization. Given the advantages of rapid delivery, in vivo stability, and independent occlusion that does not rely on intrinsic thrombosis, STBs offer an alternative gel-based embolic agent with translational potential for endovascular embolization.

Original languageEnglish (US)
JournalScience Translational Medicine
Volume8
Issue number365
DOIs
StatePublished - Nov 16 2016

Fingerprint

Biocompatible Materials
Injections
Thrombosis
Catheters
Nanocomposites
Silicates
Endovascular Procedures
Metrorrhagia
Hydrogel
Hemostatics
Gelatin
Needles
Blood Vessels
Swine
Gels
Tomography
Pressure
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

An injectable shear-thinning biomaterial for endovascular embolization. / Avery, Reginald K.; Albadawi, Hassan; Akbari, Mohsen; Zhang, Yu Shrike; Duggan, Michael J.; Sahani, Dushyant V.; Olsen, Bradley D.; Khademhosseini, Ali; Oklu, Rahmi.

In: Science Translational Medicine, Vol. 8, No. 365, 16.11.2016.

Research output: Contribution to journalArticle

Avery, RK, Albadawi, H, Akbari, M, Zhang, YS, Duggan, MJ, Sahani, DV, Olsen, BD, Khademhosseini, A & Oklu, R 2016, 'An injectable shear-thinning biomaterial for endovascular embolization', Science Translational Medicine, vol. 8, no. 365. https://doi.org/10.1126/scitranslmed.aah5533
Avery, Reginald K. ; Albadawi, Hassan ; Akbari, Mohsen ; Zhang, Yu Shrike ; Duggan, Michael J. ; Sahani, Dushyant V. ; Olsen, Bradley D. ; Khademhosseini, Ali ; Oklu, Rahmi. / An injectable shear-thinning biomaterial for endovascular embolization. In: Science Translational Medicine. 2016 ; Vol. 8, No. 365.
@article{a1a9f73aff86410b90c69d2abf478996,
title = "An injectable shear-thinning biomaterial for endovascular embolization",
abstract = "Improved endovascular embolization of vascular conditions can generate better patient outcomes and minimize the need for repeat procedures. However, many embolic materials, such as metallic coils or liquid embolic agents, are associated with limitations and complications such as breakthrough bleeding, coil migration, coil compaction, recanalization, adhesion of the catheter to the embolic agent, or toxicity. Here, we engineered a shear-thinning biomaterial (STB), a nanocomposite hydrogel containing gelatin and silicate nanoplatelets, to function as an embolic agent for endovascular embolization procedures. STBs are injectable through clinical catheters and needles and have hemostatic activity comparable to metallic coils, the current gold standard. In addition, STBs withstand physiological pressures without fragmentation or displacement in elastomeric channels in vitro and in explant vessels ex vivo. In vitro experiments also indicated that STB embolization did not rely on intrinsic thrombosis as coils did for occlusion, suggesting that the biomaterial may be suitable for use in patients on anticoagulation therapy or those with coagulopathy. Using computed tomography imaging, the biomaterial was shown to fully occlude murine and porcine vasculature in vivo and remain at the site of injection without fragmentation or nontarget embolization. Given the advantages of rapid delivery, in vivo stability, and independent occlusion that does not rely on intrinsic thrombosis, STBs offer an alternative gel-based embolic agent with translational potential for endovascular embolization.",
author = "Avery, {Reginald K.} and Hassan Albadawi and Mohsen Akbari and Zhang, {Yu Shrike} and Duggan, {Michael J.} and Sahani, {Dushyant V.} and Olsen, {Bradley D.} and Ali Khademhosseini and Rahmi Oklu",
year = "2016",
month = "11",
day = "16",
doi = "10.1126/scitranslmed.aah5533",
language = "English (US)",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "365",

}

TY - JOUR

T1 - An injectable shear-thinning biomaterial for endovascular embolization

AU - Avery, Reginald K.

AU - Albadawi, Hassan

AU - Akbari, Mohsen

AU - Zhang, Yu Shrike

AU - Duggan, Michael J.

AU - Sahani, Dushyant V.

AU - Olsen, Bradley D.

AU - Khademhosseini, Ali

AU - Oklu, Rahmi

PY - 2016/11/16

Y1 - 2016/11/16

N2 - Improved endovascular embolization of vascular conditions can generate better patient outcomes and minimize the need for repeat procedures. However, many embolic materials, such as metallic coils or liquid embolic agents, are associated with limitations and complications such as breakthrough bleeding, coil migration, coil compaction, recanalization, adhesion of the catheter to the embolic agent, or toxicity. Here, we engineered a shear-thinning biomaterial (STB), a nanocomposite hydrogel containing gelatin and silicate nanoplatelets, to function as an embolic agent for endovascular embolization procedures. STBs are injectable through clinical catheters and needles and have hemostatic activity comparable to metallic coils, the current gold standard. In addition, STBs withstand physiological pressures without fragmentation or displacement in elastomeric channels in vitro and in explant vessels ex vivo. In vitro experiments also indicated that STB embolization did not rely on intrinsic thrombosis as coils did for occlusion, suggesting that the biomaterial may be suitable for use in patients on anticoagulation therapy or those with coagulopathy. Using computed tomography imaging, the biomaterial was shown to fully occlude murine and porcine vasculature in vivo and remain at the site of injection without fragmentation or nontarget embolization. Given the advantages of rapid delivery, in vivo stability, and independent occlusion that does not rely on intrinsic thrombosis, STBs offer an alternative gel-based embolic agent with translational potential for endovascular embolization.

AB - Improved endovascular embolization of vascular conditions can generate better patient outcomes and minimize the need for repeat procedures. However, many embolic materials, such as metallic coils or liquid embolic agents, are associated with limitations and complications such as breakthrough bleeding, coil migration, coil compaction, recanalization, adhesion of the catheter to the embolic agent, or toxicity. Here, we engineered a shear-thinning biomaterial (STB), a nanocomposite hydrogel containing gelatin and silicate nanoplatelets, to function as an embolic agent for endovascular embolization procedures. STBs are injectable through clinical catheters and needles and have hemostatic activity comparable to metallic coils, the current gold standard. In addition, STBs withstand physiological pressures without fragmentation or displacement in elastomeric channels in vitro and in explant vessels ex vivo. In vitro experiments also indicated that STB embolization did not rely on intrinsic thrombosis as coils did for occlusion, suggesting that the biomaterial may be suitable for use in patients on anticoagulation therapy or those with coagulopathy. Using computed tomography imaging, the biomaterial was shown to fully occlude murine and porcine vasculature in vivo and remain at the site of injection without fragmentation or nontarget embolization. Given the advantages of rapid delivery, in vivo stability, and independent occlusion that does not rely on intrinsic thrombosis, STBs offer an alternative gel-based embolic agent with translational potential for endovascular embolization.

UR - http://www.scopus.com/inward/record.url?scp=84995680429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995680429&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aah5533

DO - 10.1126/scitranslmed.aah5533

M3 - Article

C2 - 27856795

AN - SCOPUS:84995680429

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 365

ER -